GSK completes acquisition of Aiolos Bio for up to $1.4 billion

Reuters

Published Feb 15, 2024 02:41AM ET

Updated Feb 15, 2024 11:20AM ET

LONDON (Reuters) - GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions.